Volume 7, Number 5—October 2001
Multidrug-Resistant Pseudomonas aeruginosa Producing PER-1 Extended-Spectrum Serine-β-Lactamase and VIM-2 Metallo-β-Lactamase
To the Editor: In Pseudomonas aeruginosa, secondary beta-lactamases with extended substrate specificity can be responsible for acquired resistance to the most powerful antipseudomonal beta-lactams, such as expanded-spectrum cephalosporins and carbapenems (1). A number of these enzymes have been described, including extended-spectrum serine-beta-lactamases (ESBLs) of groups 2be and 2d (e.g., PER-1 and various OXA-type enzymes) (2,3) and metallo-beta-lactamases of group 3 (e.g., IMP-1 and the recently described VIM-1 and VIM-2 enzymes) (2,4,5). The secondary ESBLs can degrade penicillins, expanded-spectrum cephalosporins, and monobactams (but not carbapenems) and are often susceptible to serine-beta-lactamase inhibitors (1-3). The secondary metallo-beta-lactamases, on the other hand, are notable for their carbapenemase activity and can degrade virtually all beta-lactams except monobactams, while being resistant to the currently available inhibitors (1,2,5,6).
On March 2000, a multidrug-resistant P. aeruginosa (isolate VA-182/00) was isolated in pure culture from a bronchial washing of a 58-year-old patient with multiple myeloma. The patient had been admitted 15 days earlier to the Varese University Hospital with a diagnosis of pneumonia and had been treated with ciprofloxacin (0.5 g twice a day) plus piperacillin (2 g three times a day) for 12 days, and then with imipenem/cilastatin (0.5 g three times a day). No cultures of respiratory tract specimens were done earlier in hospitalization. Multiple myeloma had been diagnosed in 1997, and the patient had been treated with multiple cycles of antiproliferative chemotherapy and had received autologous peripheral blood stem cell transplantation. According to clinical records, P. aeruginosa had not been isolated previously during this patient's protracted illness. In vitro susceptibility testing showed that the P. aeruginosa isolate was resistant to mezlocillin, ceftazidime, cefepime, aztreonam, imipenem, meropenem, gentamicin, tobramycin, netilmicyn (MICs, >128 µg/mL), amikacin (MIC, 64 µg/mL), ciprofloxacin and levofloxacin (MICs, >32 µg/mL). Only piperacillin and piperacillin/tazobactam had MIC values slightly lower than the breakpoints for resistance (64 µg/mL and 48/4 µg/mL, respectively), although--considering the normal MICs of piperacillin for susceptible P. aeruginosa (2-8 µg/mL)--it was evident that the isolate also had considerable biological resistance to these drugs. A double disk-diffusion test, carried out with standard disks placed 20 mm apart (center-to-center), showed synergy between clavulanate and aztreonam. The treatment was changed to piperacillin/tazobactam (4 g four times a day), and a slow recovery ensued over a 30-day period. The patient died 3 months later following a relapse of the underlying malignancy.
The unusually high carbapenem MICs exhibited by VA-182/00 suggested production of a secondary metallo-beta-lactamase, while the synergy between clavulanate and aztreonam suggested production of a secondary serine ESBL. A crude extract of that isolate, assayed spectrophotometrically (7), exhibited imipenem-hydrolyzing activity (94 nmol/min/mg protein, inhibited by EDTA) as well as aztreonam-hydrolyzing activity (11 nmol/min/mg protein, resistant to EDTA). Analytic isoelectric focusing (IEF) of the extract, followed by development with the nitrocefin chromogenic substrate (7), showed three bands of beta-lactamase activity of pIs 5.4, 5.6, and 6.3, suggesting the presence of at least three different secondary enzymes. A colony-blot hybridization with probes for the blaIMP, blaVIM, and blaPER resistance genes (all of which have been previously detected in P. aeruginosa clinical isolates from the same hospital [8,9; Luzzaro F, unpub. data]) yielded positive results with both the blaVIM and the blaPER probes. Amplification of the resistance genes by polymerase chain reaction (PCR) with primers VIM/DIA-f (5'-CAgATTgCCgATggTgTTTgg) and VIM/DIA-r (5'-AggTgggCCATTCAgCCAgA) for blaVIM genes (4,5) and BLAPER-f (5'-gggACA(g/A)TC(g/C)(g/T)ATgAATgTCA) and BLAPER-r (5'-ggg(C/T)(g/C)gCTTAgATAgTgCTgAT) for blaPER genes (9), yielded amplicons of the expected sizes (522 and 966 bp, respectively). Direct amplicon sequencing identified the two beta-lactamase determinants as blaVIM-2 (5) and blaPER-1 (10), respectively, a finding consistent with the pIs 5.6 and 5.4 beta-lactamase bands detected in IEF (3,5). Conjugative transfer of the resistance determinants to Escherichia coli proved unsuccessful. In a Southern blot analysis of total undigested DNA from VA-182/00, both the blaVIM and blaPER probes apparently hybridized to the chromosomal DNA band; no plasmid bands recognized by either probe were detected. A PCR experiment with primers OXA10-f (5'-ggAACAAAgAgTTCTCTgCC) and OXA105-r (5'-TTAgCCACCAATgATgCC(C/T)TC), suitable for amplification of blaOXA genes of the OXA-10 group, did not yield an amplicon of the expected size (719 bp), suggesting that the pI 6.3 beta-lactamase band detected by IEF did not correspond to an enzyme of this group.
This is the first observation of a P. aeruginosa clinical isolate simultaneously producing a secondary PER-1 ESBL and a secondary metallo-beta-lactamase. The finding, observed in a hospital where both the resistance genes (blaPER-1 and blaVIM-2) had been detected separately among clinical isolates, underscores the possibility of the emergence of new threatening combinations of resistance determinants among nosocomial pathogens. In fact, the recruitment of similar resistance determinants within a single P. aeruginosa strain can determine a resistance phenotype to virtually all the available antipseudomonal beta-lactams, an occurrence that can be particularly dramatic when, as in the present case, resistance to beta-lactams is associated with resistance against aminoglycosides and fluoroquinolones. In this case, only piperacillin (which appears to be a relatively poor substrate for both enzymes [3,5]) retained moderate activity in vitro and, administered at high dosage in combination with tazobactam, was apparently effective in vivo. Should a similar resistance phenotype disseminate, it might have strategic implications for the development of new beta-lactamase inhibitors and for selection of beta-lactam compounds to associate wth inhibitors.
This work was supported in part by grant no. FMRX-CT98-0232 from the European Training and Mobility of Researchers Network on metallo-beta-lactamases.
- Livermore DM. Beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev. 1995;8:557–84.
- Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211–33.
- Nordmann P, Ronco E, Naas T, Duport C, Michel-Briand Y, Labia R. Characterization of a novel beta-lactamase from Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1993;37:962–9.
- Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Cloning and characterization of blaVIM, a new integron-borne metallo-beta-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother. 1999;43:1584–90.
- Poirel L, Naas T, Nicholas D, Collet L, Bellais S, Cavallo JD, Characterization of VIM-2, a carbapenem-hydrolyzing metallo-beta-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother. 2000;44:891–7.
- Franceschini N, Caravelli B, Docquier JD, Galleni M, Frere JM, Amicosante G, Purification and biochemical characterization of the VIM-1 metallo-beta-lactamase. Antimicrob Agents Chemother. 2000;44:3003–7.
- Livermore DM, Williams JD. Beta-lactams: mode of action and mechanisms of bacterial resistance. In: Lorian V, editor. Antibiotics in Laboratory Medicine. 4th ed. Baltimore: William & Wilkins; 1996. p. 502-78.
- Luzzaro F, Mantengoli E, Perilli M, Lombardi G, Orlandi V, Orsatti A, Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum beta-lactamase. J Clin Microbiol. 2001;39:1865–70.
- Pereira M, Perilli M, Mantengoli E, Luzzaro F, Toniolo A, Rossolini GM, PER-1 extended-spectrum beta-lactamase production in an Alcaligenes faecalis clinical isolate resistant to expanded-spectrum cephalosporins and monobactams from a hospital in Northern Italy. Microb Drug Resist. 2000;6:85–90.
- Nordmann P, Naas T. Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases. Antimicrob Agents Chemother. 1994;38:104–14.
Suggested Citation for this article: Docquier J-D, Luzzaro F, Amicosante G, Toniolo A, Rossoline GM. Multidrug-Resistant Pseudomonas aeruginosa Producing PER-1 Extended-Spectrum Serine-β-Lactamase and VIM-2 Metallo-β-Lactamase. Emerg Infect Dis [serial on the Internet]. 2001, Oct [date cited]. http://dx.doi.org/10.3201/eid0705.010528
Comments to the EID Editors
Please contact the EID Editors via our Contact Form.
- Page created: April 26, 2012
- Page last updated: April 26, 2012
- Page last reviewed: April 26, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)